<DOC>
	<DOCNO>NCT01839032</DOCNO>
	<brief_summary>Patients ( pt ) stage IIIA/IIIB NSCLC receive NVBiv 25 mg/m² + CDDP 80 mg/m² D1 NVBo 60 mg/m² D8 every 3 week ( q3w ) 2 cycle induction . Pts response non change receive NVBo 20 mg fix dose D1 D3 D5 + CDDP 80 mg/m² D1 q3w 2 cycle RT ( 66 Gy/6.5 w ) .</brief_summary>
	<brief_title>Oral Vinorelbine Induction Chemotherapy Followed Concomitant Chemoradiotherapy</brief_title>
	<detailed_description>Vinorelbine ( NVB ) + CDDP consider standard trt induction concomitantly RT ( Vokes , Fournel , Krzakowski ) . NVBo simplify administration trt provide efficacy intravenous NVB ( NVBiv ) . In order ass improve tolerance , trial start NVBiv NVBo + CDDP induction follow fractionated administration NVBo + CDDP RT .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>histologically cytologically confirm stage IIIA ( N2 ) , dry IIIB previously untreated inoperable NSCLC , 18 75 year old , Karnofsky Performance Status ( KPS ) ≥ 80 % , weight loss ≤ 10 % within previous 3 month , normal organ function eligible . least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST version 1.0 ) [ 10 ] . stage I , II , IIIA ( except N2 ) , IIIB pleural effucion stage IV , pregnant breastfeed woman . Women Childbearing Age : Women childbearing potential take reliable contraceptive measure Symptomatic Neuropathy &gt; grade 1 , associate Pathology and/or control disease ( cardiac insuficiency , myocardial infarction within 3 month inclusion ; hypertension , arythmia uncontroled hypercalcémia ; infection requiering iv antibiotic administration within 2 week inculion ) , associate cancer exception cervical carcinoma situ skin cancer basocellular correctely treat , Previous treatment antineoplasic , Known hypersensibility drug similar chemical structure ti study . important malabsorbtion syndrom disease gastrointestinal track , Participation another clinical trial within 30 day inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>